


## Azido-PEG3-Val-Cit-PAB-PNP

<b>Cat. No.:</b>	HY-140150
<b>CAS No.:</b>	2055047-18-0
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>47</sub> N <sub>9</sub> O <sub>12</sub>
<b>Molecular Weight:</b>	773.79
<b>Target:</b>	ADC Linker; PROTAC Linkers
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (161.54 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.2923 mL	6.4617 mL	12.9234 mL	
5 mM	0.2585 mL	1.2923 mL	2.5847 mL	
10 mM	0.1292 mL	0.6462 mL	1.2923 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)<sup>[1]</sup>. Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs<sup>[2]</sup>. Azido-PEG3-Val-Cit-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

#### IC<sub>50</sub> & Target

PEGs	Protease Cleavable Linker	Cleavable Linker
------	---------------------------	------------------

#### In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker<sup>[1]</sup>. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32.

[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA